Trade

Blue Jet Healthcare share price

High risk
  • 47%Low risk
  • 47%Moderate risk
  • 47%Balanced risk
  • 47%High risk
  • 47%Extreme risk
  • 548.60(0.36%)
    December 9, 2025 15:43:01 PM IST
    • NSE
    • BSE
  • Vol : 305.88 K (NSE + BSE)
    Last 20 day avg : 359.47 K

Blue Jet Healthcare is trading 0.36% upper at Rs 548.60 as compared to its last closing price. Blue Jet Healthcare has been trading in the price range of 554.05 & 534.00. Blue Jet Healthcare has given -2.82% in this year & -3.10% in the last 5 days. Blue Jet Healthcare has TTM P/E ratio 31.01 as compared to the sector P/E of 30.57.There are 6 analysts who have initiated coverage on Blue Jet Healthcare. There are 3 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.The company posted a net profit of 52.14 Crores in its last quarter.Listed peers of Blue Jet Healthcare include Sun Pharmaceutical Industries (-1.05%), Dr Reddy's Laboratories (-1.48%), Cipla (-0.45%).The Mutual Fund holding in Blue Jet Healthcare was at 1.77% in 30 Sep 2025. The MF holding has increased from the last quarter. The FII holding in Blue Jet Healthcare was at 1.83% in 30 Sep 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Dec 09, 2025, 03:21 PM UTC

  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.02
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.22
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    1.42
    Indicates Fair Valuation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    -
Price range
Day Range
Lowest
534.00
Highest
554.05
52 week range
Lowest
491.65
Highest
1,028.20
Blue Jet Healthcare Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
Neutral
1,776.45-1.054,27,469.5137.946.040.880.50
Dr Reddy's Laboratories
-
1,248.40-1.481,04,189.2418.803.170.632.34
Cipla
Bearish
1,490.70-0.451,20,297.9723.333.940.850.81
Torrent Pharmaceuticals
Bullish
3,759.450.041,27,328.3266.6416.920.8417.62
Divi's Laboratories
Moderately Bearish
6,293.00-0.561,67,023.7578.2711.470.460.01
Mutual Fund Ownership
View all
Samco Special Opportunities Fund Regular Growth
NA
  • Amount Invested (Cr.) 3.95
  • % of AUM 2.44
TrustMF Small Cap Fund Regular Growth
NA
  • Amount Invested (Cr.) 18.44
  • % of AUM 1.90
UTI Small Cap Fund Regular Growth
2/5
  • Amount Invested (Cr.) 45.80
  • % of AUM 1.01
WhiteOak Capital Pharma and Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.88
  • % of AUM 0.56
Samco Multi Cap Fund Regular Growth
NA
  • Amount Invested (Cr.) 1.17
  • % of AUM 0.32
Blue Jet Healthcare Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-11-04Quarterly Results
2025-07-22Quarterly Results
2025-05-14Audited Results, Final Dividend & Others
2025-01-29Quarterly Results
2024-10-29Quarterly Results
About the company Blue Jet Healthcare
  • IndustryBiotechnology & Drugs
  • ISININE0KBH01020
  • BSE Code544009
  • NSE CodeBLUEJET
Blue Jet Healthcare Limited is an India-based company, specializing in manufacturing integrated contrast media, artificial sweeteners and its salts, as well as niche pharmaceutical intermediaries and active pharmaceutical ingredients (APIs). The Company serves as a business-to-business (B2B) company. Its integrated contrast media intermediate product categories include x-ray contrast media intermediates and MRI contrast media intermediates. Its x-ray contrast media intermediates include non-ionic APIs and ionic APIs. It manufactures saccharin and supplies to healthcare, pharma, animal feed, food and beverages industries globally. The Company's offerings include insoluble saccharin, saccharin sodium and insoluble saccharin. Its advance pharmaceutical intermediates and API products include Vanillic Acid, Docusate Sodium and TosMIC. It offers end-to-end integrated solutions from process development to commercialization of NCEs, advance intermediates, APIs and building blocks.
  • Management Info
  • Akshay AroraExecutive Chairman of the Board
  • Ganesh KaruppannanChief Financial Officer
  • Vimalendu SinghChief Operating Officer
  • Sweta PoddarCompliance Officer, Company Secretary
  • Shiven AroraManaging Director, Executive Director
  • Popat KedarExecutive Whole-Time Director
  • Naresh ShahExecutive Director
Blue Jet Healthcare Share Price FAQs

Blue Jet Healthcare is trading at 548.60 as on Tue Dec 09 2025 10:13:01. This is 0.36% upper as compared to its previous closing price of 546.65.

The market capitalization of Blue Jet Healthcare is 9511.97 Cr as on Tue Dec 09 2025 10:13:01.

The average broker rating on Blue Jet Healthcare is Buy. The breakup of analyst rating is given below -

  • 3 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 1 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Blue Jet Healthcare is 1028.20 whereas the 52 wk low is 491.65

Blue Jet Healthcare can be analyzed on the following key metrics -

  • TTM P/E: 31.01
  • Sector P/E: 30.57
  • Dividend Yield: 0.22%
  • D/E ratio: 0.02

Blue Jet Healthcare reported a net profit of 305.20 Cr in 2025.

The Mutual Fund Shareholding was 1.77% at the end of 30 Sep 2025.